Volume 23 (2025): Issue 3.5 (Mar 2025): Abstracts from the NCCN 2025 Annual Conference

in Journal of the National Comprehensive Cancer Network
Online ISSN:
1540-1413
Print ISSN:
1540-1405
Cover Journal of the National Comprehensive Cancer Network
Young Investigator Awards
Best Practices in Implementation and Use of Clinical Practice Guidelines
BPI25-003: Hydrocortisone Instead of Dexamethasone As Premedication for Paclitaxel
BPI25-004: Evaluating the Role of Social Determinants of Health (SDoH) in Predicting Surgical Delays and Impact on Healthcare Resources Utilization in Early-Stage NSCLC
BPI25-005: Molecular Biomarker Testing Patterns and Turn-Around Time in US Patients With Advanced Non-Small Cell Lung Cancer
BPI25-006: Triage for Screening Programs: Colour Coding High-Risk Patients
BPI25-007: Digital Tools to Transform NCCN Guidelines Into Germline Genetic Counseling
BPI25-008: Improving Patient Access and Adherence: The Role of an Electronic Health Record (EHR)-Embedded Clinical Decision Support (CDS) Tool in Specialty Drug Management
BPI25-010: Increasing Access and Reducing Barriers to Colorectal Cancer Screening (CRCS) Among Low-Income and/or Uninsured Adults Ages 45 to 75 in Texas Through a FIT-First Approach: Project 80%
BPI25-011: A Case Study of Implementation of Clinical Decision Support Tools in the Expansion of Use of Bispecific T-Cell Engager (BiTE) Therapies in a Community Hospital System
BPI25-012: Developing an Artificial Intelligence Tool for Personalized Breast Cancer Treatment Plans Based on the NCCN Guidelines
BPI25-014: Pacritinib in Patients With Intermediate-1 Risk Myelofibrosis: Outcomes From Post-Hoc Analysis of Two Phase 3 Studies
BPI25-015: Implementing a No-Cost Strategy to Minimize Blood Product Waste in a High-Volume Hematology/Oncology Intermediate Care Unit
BPI25-016: Real-World Outcomes of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Insights From a Single Center in the Deep South
BPI25-017: A Novel Integrated Classification Schema for Molecular Findings by Potential Clinical Actionability: A Tool for Assessment of Real-World Cancer Care in the Targeted Therapy Era
BPI25-018: Impact of Early Palliative Care on Outcomes in Small Cell Lung Cancer
BPI25-019: Empirical Study to Estimate Real World Impact of Delay in EGFR Testing on Healthcare Resource Utilization and Cost Burden Among Early-Stage NSCLC Patients
BPI25-020: Compliant Care and Quality Outcomes in Multiple Myeloma
Bioinformatics/Information Technology Sciences
BIO25-022: Why Don’t They Want to Wear Sunscreen? Quantifying Anti-Sunscreen Messaging on TikTok
BIO25-023: Patient Perceptions of Artificial Intelligence in Healthcare: Findings from the Cancer Experience Registry
BIO25-024: Real-Time Clinical Trial Data Library in Non-Small Cell Lung (NSCLC), Prostate (PC), and Breast Cancer (BC) to Support Informed Treatment Decisions: Now a Reality With a Fine-Tuned Large Language Model (LLM)
BIO25-025: AI Tracking Multidisciplinary Decision Making: Enabling a Regional Support Tool
BIO25-026: Innovating a Digital Patient Navigation Platform (DPNP) to Help Patients With Melanoma Access Multidisciplinary Cutaneous Oncology Care
BIO25-027: Addressing Early Diagnosis Challenges: Utilizing C the Signs Clinical Decision Support Platform for Pancreatic Cancer Risk Assessment
BIO25-029: Benefits Of Telemedicine in Oncology Multi-Disciplinary Feedback
Case Reports
CRE25-030: Rare Case of Immune Checkpoint Inhibitor Induced Myocarditis and Myositis: Diagnosis and Management
CRE25-031: Nonbacterial Thrombotic Endocarditis in Early Stage Lung Adenocarcinoma
CRE25-032: Carfilzomib-Induced Thrombotic Microangiopathy in Multiple Myeloma
CRE25-033: A MET Amplified Metastatic Esophageal Adenocarcinoma Demonstrates Response to the MET Inhibitor Capmatinib
CRE25-034: Langerhans Cell Histiocytosis: Presenting as Polyuria, Polydipsia, and Multiple Skull Lesions
CRE25-035: Vascular Endothelial Growth Factor Inhibitor-Induced Radiation Recall Tracheitis in a CASTLE Carcinoma of the Thyroid Patient
CRE25-036: Breast Implant Associated Squamous Cell Carcinoma (BIA-SCC): A Mayo Clinic Multidisciplinary Approach to Treatment
CRE25-037: Paraneoplastic Syndrome in Undifferentiated Pleomorphic Sarcoma Demonstrates Acquired Antithrombin III Deficiency as Risk Factor for Cancer-Related Morbidity
CRE25-038: Worsening COPD From Hyperviscosity: A Case Report of Waldenström Macroglobulinemia
CRE25-040: A Case of Stage IV NSCLC With MET Exon 14 Mutation With Durable Response to MET Inhibitor Following Cessation of Therapy Due to Toxicity: Insights for Treatment Strategies
CRE25-041: Pneumocephalus in the Setting of Endometrial Adenocarcinoma: A Case Report
CRE25-042: Advanced Fibrosis, TP53 Variants, and Erythroid Differentiation: Diagnostic Harbingers of ERCC6L2-Related Bone Marrow Failure Syndrome?
CRE25-044: A Case Series of Immunotherapy-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis
CRE25-045: Delayed Detection of Liver Metastasis in Granulosa Cell Tumor Due to Healthcare Disparities: A Case Report and Literature Review
CRE25-046: Gastric-Type Mucinous Endocervical Adenocarcinoma: A Case Report and Literature Review
CRE25-047: Avapritinib Induced Pseudoprogression in a Gastrointestinal Stromal Tumor With a PDGFRA Exam 18 842 Mutation
CRE25-048: A Rare Tumor Presentation in a Postpartum Female: Case Report of Malignant Peripheral Nerve Sheath Tumor Accompanying Neurofibromatosis Type I Diagnosis
CRE25-049: A Therapeutic Conundrum: Malignancy-Associated Thrombotic Thrombocytopenic Purpura (TTP)
CRE25-050: Durable Response to Immunotherapy Rechallenge With Double Immunotherapy for a Patient With Advanced Non-Small Cell Lung Cancer
CRE25-051: Differentiation Syndrome Masked As Encephalopathy in Patient With Recurrent Acute Myeloid Leukemia (AML)
Clinical Oncology
CLO25-053: Real-World Evidence of Survival in Patients With Metastatic NSCLC Treated With First-Line Immune Checkpoint Inhibitors Beyond Progression
CLO25-054: Long Term Follow Up of Patients Undergoing High Dose Chemotherapy and Autologous or Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma
CLO25-055: Metastasis-Free Survival Prediction With the 40-Gene Expression Profile Test in Patients With Cutaneous Squamous Cell Carcinoma Risk Stratified According to the National Comprehensive Cancer Network Guidelines
CLO25-056: Does Adjuvant Therapy Improve Survival Following Upfront Esophagectomy? Real World Evidence - Based on National Cancer Database Analysis
CLO25-057: Exploring CD30+ Cutaneous Lymphomas: A Retrospective Study on Clinical Outcomes and Prognostic Markers
CLO25-058: First-in-Human, Multicenter Phase 1 Study of the Bromodomain 2 Inhibitor ABBV-744 in Relapsed/Refractory Acute Myeloid Leukemia
CLO25-059: Exploring Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Squamous Cell Carcinoma (LSCC) in North America
CLO25-060: Baseline Imaging in the Staging of Merkel Cell Carcinoma
CLO25-061: 7-Gene Biosignature Reclassified Women With DCIS Meeting NCCN Guideline (RTOG 9804-Like) Low-Risk Criteria as Molecular High Risk
CLO25-062: Prevalence of Cannabis Use Disorder Among Hospitalized Elderly Cancer Survivors: Nationwide Trends and Disparities (2016–2020)
CLO25-063: Immune Checkpoint Inhibitor Therapy and the Risk of Second Primary Malignancies in Melanoma and Lung Cancer Patients
CLO25-065: MGUS and SMM Patients Specialist Follow Up and Laboratory Surveillance Rates in a Community Safety Net Hospital Setting
CLO25-066: Prognostic Role of Pre-Transplant EASIX on Non-Relapse Mortality and Overall Survival in Allogeneic Stem Cell Transplantation: A Meta-Analysis
CLO25-067: Risk of Trastuzumab Deruxtecan (T-DXd) Associated Interstitial Lung Disease (ILD)/Pneumonitis: A Real-World Population-Based Propensity-Matched Analysis
CLO25-069: Single Dose Nivolumab and Ipilimumab Treatment Causing Complete and Durable Response in Extensive Stage Small Cell Lung Cancer Complicated By Severe Sensory Autoimmune Neuropathy
CLO25-070: Effects and Mechanisms of CD16+/-NK Cells on Ovarian Malignant Tumor Cells Platinum-Based Drug Responsiveness in Tumor Microenvironment
CLO25-071: The Impact of ChemoMouthpiece Device on Analgesic Use for Oral Pain in a Randomized, Prospective, Multi-Center Trial for Patients Undergoing Stomatoxic Chemotherapy
CLO25-072: A Multicenter, Randomized, Controlled, Non-Inferiority Study of Narlumosbart Compared With Denosumab in the Treatment of Bone Disease in Patients With Multiple Myeloma
CLO25-073: Rare Tumors of the Larynx
CLO25-074: Outcomes to Immune Checkpoint Inhibitors (ICIs) According to Programmed Death-Ligand 1 (PD-L1) Levels in KRAS-, KEAP1-, STK11-Mutant Lung Squamous Cell Carcinoma (LSCC)
CLO25-075: Characterization of Lung Cancer Shedding and Spread Through Air Spaces in Lung Adenocarcinoma
CLO25-078: Deciphering Risk of Early Biochemical Recurrence in Prostate Cancer Prior to Definitive Therapy
CLO25-080: Outcomes of Extreme Low PD-L1 Expression in Advanced Non-Small Cell Lung Cancer: Implications for Treatment Approaches
CLO25-081: The Effect of Delay of Adjuvant Chemotherapy on the Overall Survival in Early-Stage Breast Cancer
CLO25-082: Predictors of Survival in Breast Cancer With Brain Metastases: A Multi-Center Institutional Experience
CLO25-083: Immune-Related Adverse Events in Women With Early and Advanced Triple-Negative Breast Cancer Treated With Pembrolizumab: A Multi-Center Analysis
CLO25-084: Metastatic Neck Involvement in Oral Squamous Cell Carcinoma: A Retrospective Clinicopathological Study
CLO25-085: A Structured Approach in Suicide Prevention – Safety Plan Intervention for Cancer Patients
CLO25-087: Low Serum Pseudocholinesterase Level Predicts HCC Mortality As Accurately As the ALBI or MESIAH Score
CLO25-088: Endobronchial Malignant Granular Cell Tumor (MGCT) With BRAF Mutation: Case Report
CLO25-089: The Prognostic Value of the Endothelial Activation and Stress Index (EASIX) in Predicting Clinical and Survival Outcomes and Treatment Response for Patients Undergoing Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
CLO25-090: MiR-31 as a Predictive Biomarker of Cetuximab Efficacy in Metastatic Colorectal Cancer Patients
CLO25-091: Impact of PD-L1 Expression on Immune-Related Adverse Events (irAEs) in Non-Small Cell Lung Cancer (NSCLC): Real-World Data From Community Oncology Practice
CLO25-093: Surgical Timing and Its Effect on Disease Progression in Non-Small Cell Lung Cancer: A Stage-Specific Analysis
CLO25-095: Baseline Genomic Alterations as Predictors of Response to Anti-HER2 Therapy in HER2-Amplified Advanced Colorectal Cancer (aCRC)
CLO25-096: miR-126 in Prostate Cancer: A Systematic Review of Its Impact on Cancer Progression and Treatment
CLO25-097: Randomized Phase II Study of Pembrolizumab 200mg q12 Weeks Versus Standard-of-Care (SOC) Dosing in Stage IV Non-Small Cell Lung Cancer (NSCLC) With Prior Clinical Benefit to Pembrolizumab Monotherapy
CLO25-099: Lenvatinib With Pembrolizumab in Advanced Biliary Tract Cancer
CLO25-100: Improving Germline Testing in At-Risk Patients With Prostate Cancer
CLO25-101: Cost-Effectiveness of Dose Reduction of Antibody-Drug Conjugates for Breast Cancer
CLO25-102: Survival Outcomes in Breast Cancer Patients With Diseased Axillary Lymph Nodes: The Role of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy.
Correlative/Genomic
CGE25-103: Impact of Vaping on CDC42, RAC1, and SDC1 Gene Expression: Implications for Cancer Progression
CGE25-104: The 31-GEP Identifies Patients With Early-Stage I-IIA Cutaneous Melanoma at High Risk of Melanoma-Specific and Overall Mortality
CGE25-105: Microrna Expression Profiles in Non-Small Cell Lung Cancer Related Pleural Effusion and Its Prognostic Significance in Treatment Response and Survival Outcome
CGE25-106: MHC II More Effectively Predicts Response to Pembrolizumab Than PD-L1 in HER2 Negative Patients
CGE25-107: Capture Efficacy of Genomic Panels for NCCN-Recommended and Clinical Trial Associated Biomarkers
CGE25-108: Uncovering APOBEC Mutational Signatures in Cancer: The Power of Whole Genome Sequencing for Comprehensive Genomic Profiling
CGE25-109: Mapping Common Oncogene Protein-Protein Interactions to Discover New Targets in HRD-Negative Ovarian Cancer
CGE25-110: Identification of an Elusive CBFA2T3-GLIS2 Fusion Variant in Acute Megakaryoblastic Leukemia by Whole Genome Sequencing
CGE25-111: Enhancing Oncology Treatment Personalization through Plasma Proteomics and Machine Learning
CGE25-112: Analyzing the Prognostic Significance of Common Mutations in Pancreatic Cancer (PC) via Next Generation Sequencing (NGS)
Epidemiology/Risks/Prevention
EPR25-113: Mortality and DALY in Uterine Cancer Patients With High Body Mass Index: A Comparative Study of the United States and Global Data (1990–2021)
EPR25-115: Pre-Menopausal Obesity Duration and Breast Cancer Risk in Women With Family History of Breast Malignancy
EPR25-116: Survival Analysis of Four Common Cancers in Antigua and Barbuda, 2017-2021: A Retrospective Study
EPR25-117: Cardiovascular Events in Patients Diagnosed With Light Chain Amyloidosis in the USA: A Real-World Analysis Utilizing Electronic Health Records
EPR25-118: A Comparison of Demographic Characteristics of Individuals With Head and Neck Cancer (HNC) Among Multiple Datasets
EPR25-119: Primary Cardiac Soft Tissue Sarcoma: A Retrospective Analysis
EPR25-122: Statin Use and Reduced Incidence of Colorectal Cancer in Veterans: A Nested Case-Control Study
EPR25-123: Brenner Tumor Prognostication Based on Race and Laterality
EPR25-124: Epidemiology of Giant Cell Glioblastoma: A Surveillance, Epidemiology, and End Results (SEER) Analysis
EPR25-125: Therapy-Induced Acute Myeloid Leukemia in Multiple Myeloma Patients: Database Analysis of Risk, Overall Survival and Prognostic Factors
EPR25-127: The Changing Landscape of Venous Thromboembolism in Breast Cancer: Trends Over the Years 2016-2020
EPR25-130: Multi-Year Review of the Management of Patients in a High-Risk Breast Clinic
EPR25-131: Hematologic Adverse Effects Profile of Immune Checkpoint Inhibitors: A Real-World Pharmacovigilance Study Using FAERS Database
EPR25-132: Hospital-Based Cancer Registry (HBCR) Data Analysis for Women at a Tertiary Care Center in North India
EPR25-135: Attitudes and Knowledge of Primary Human Papilloma Virus Testing Among Women Attending Primary Healthcare
EPR25-136: Prostate Cancer and Geography: How Location Affects In-Hospital Outcomes? A Nationwide Analysis
EPR25-137: Epidemiology and Prognostication of Malignant Glomus Tumor
EPR25-138: Glioblastoma Multiforme: A SEER STAT Analysis of Epidemiological, Laterality, and Anatomical Prognostic Indicators
EPR25-140: Socioeconomic and Clinical Determinants of Survival in Young Breast Cancer Patients: A Population Based Study
Outcomes and Health Services Research
HSR25-141: Adolescent and Young Adult Cancer Patients: Our Most Financially Vulnerable Demographic
HSR25-142: Assessment of Community Oncology Palliative and Supportive Care Program in Improving Patient’s Quality of Life: A Patients Perspective
HSR25-143: Meta-Analysis of Phase 3 Randomized Controlled Trials to Evaluate the Incidence of Systemic Toxicities in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin
HSR25-144: Clinical Outcomes for Leukemia Patients Following Hematopoietic Stem Cell Transplant: An Analysis of the National Inpatient Sample
HSR25-146: How Mental Health and Substance Use Drive Cancer Disparities in Urban Communities
HSR25-147: Time Toxicity of Different Frontline Regimens in EGFR Mutated Non-Small Cell Lung Cancer
HSR25-148: The State of Lung Cancer in Alabama
HSR25-149: Racial Disparities in Non-Small Cell Lung Cancer Survival Outcomes: A Systemic Review and Meta-Analysis
HSR25-150: Meta-Analysis of Randomized Controlled Trials (RCTs) to Evaluate the Incidence of Health-Related Quality of Life (HRQOL) Events in Patients with Primary Advanced or Recurrent Endometrial Cancer Treated With First-Line Immunochemotherapy
HSR25-151: EPIC Patient Portal Functionality: An Equity Analysis in Vulnerable Cancer Patients
HSR25-152: Incidence of Hematologic Adverse Events in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Treated With Amivantamab: A Meta-Analysis of Phase III Randomized Controlled Trials
HSR25-153: Patient Preferences and Willingness to Accept Trade-Offs for a Favorable Treatment Response Among Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
HSR25-154: Treatment Patterns and Prognosis of Patients With HER2-Negative Early Breast Cancer and Germline Pathogenic Variants in BRCA1, BRCA2, ATM, CHEK2 and PALB2
HSR25-155: Racial Disparities in Palliative Care (PC) Access Among Patients With Malignant Brain Tumors (MBT): A Retrospective Analysis Using the National Inpatient Sample (2014–2020)
HSR25-156: Myelosuppression and Healthcare Resource Utilization in Community Oncology Patients With Limited-Stage Small Cell Lung Cancer (LS-SCLC) Receiving First-Line Therapy With or Without Trilaciclib
HSR25-157: The Epidemiology and Clinical Outcomes of Lung Cancer Patients With Hypercalcemia: Evidence From a National Inpatient Database.
HSR25-158: Elevating Cancer Care: Launching a Comprehensive Nutrition and Wellness Program at a Multisite Cancer Center
HSR25-159: Real-World Effectiveness of First-Line Osimertinib for Patients in the US With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer Who Were Eligible for Medicare
HSR25-160: Evaluating Patient Characteristics, Treatment Patterns, Clinical Outcomes, and Health Care Resource Use in Pemigatinib-Treated Cholangiocarcinoma (CCA) Patients: A Focus on Cancer of Unknown Primary
HSR25-161: Potential Factors Impacting Adherence With National Comprehensive Cancer Network Radiation Therapy Guidelines for Early-Stage Breast Cancer.
HSR25-162: Long-term Outcomes in Patients With Tumor Lysis Syndrome and Comorbid Gout: A Propensity-Matched Study From the Global Federated Health Research Network
HSR25-164: Mapping Patient Reported Side-Effect Incidence to Degradation of Health-Related Quality of Life Dimensions in Lymphoma and Chronic Lymphocytic Leukemia – A Study From the Lymphoma Coalition’s 2024 Global Patient Survey on Lymphomas & CLL
HSR25-165: The Effectiveness of Implementing a Community-Based Lung Clinic in Rural Community Cancer Center
HSR25-166: Linking COVID-Related Distress and Mental Health Service Utilization Among Allogeneic Hematopoietic Stem Cell Transplant Patients
HSR25-167: Real-World Study Demonstrates Lack of Biomarker-driven Care in First-Line Treatment for Advanced/Metastatic Non-Small Cell Lung Cancer That Received Next-Generation Sequencing Testing
HSR25-168: Survival Analysis for Early Onset and Very Early Onset Colon Cancer Using National Cancer Database (NCDB) 2004-2021
HSR25-170: Investigating Socioeconomic and Racial Disparities in Pathologic Response and Survival Outcomes in Triple-Negative Breast Cancer Post-Neoadjuvant Chemotherapy: Insights From the National Cancer Database
HSR25-171: Risk of Health-Related Quality of Life (HRQOL) Events in Patients with EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated With Amivantamab: A Meta-Analysis of Phase III Randomized Controlled Trials
HSR25-172: Meta-Analysis of Phase 3 Randomized Controlled Trials to Evaluate the Incidence of Infectious Adverse Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin
HSR25-173: Impact of Social Determinants of Health on Lung Cancer Screening and Small Cell Lung Cancer Outcomes in a County Hospital
HSR25-174: Impact of Adverse Events on Quality of Life in Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors – Results From the Survey on Humanistic Burden of Intolerance to First or Second TKIs (SHIFT) Study
HSR25-175: Meta-Analysis of Randomized Controlled Trials (RCTs) to Evaluate the Incidence of Venous Thromboembolism (VTE) and Immune-Related Adverse Events (iRAEs) in Patients With Primary Advanced or Recurrent Endometrial Cancer Treated With Immunochemotherapy
HSR25-176: Efficacy of Immunochemotherapy in Primary Advanced or Recurrent Endometrial Cancer: A Systematic Review and Meta-Analysis of Phase II/III Randomized Controlled Trials (RCTs)
HSR25-177: Impact of the Surin One-Stop Service (S.O.S) System on Reducing Patient Travel and Improving Cancer Treatment Access in Rural Thailand
HSR25-178: Initial Clinical Presentation (ICP) and Pre-Diagnostic Journey During 18 Months Before a First Non-Small Cell Lung Cancer (NSCLC) Diagnosis: US Retrospective Cohort Study
HSR25-179: Pancreatic Cancer: Expediting Histopathological Diagnosis to Reduce Time to Treatment Initiation
HSR25-180: Real-World (rw) Characteristics, Treatment (tx) Patterns and Clinical Outcomes in Patients (pts) With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Received Chemoradiotherapy (CRT)
HSR25-181: Assessment of Content Validity of the Functional Assessment of Cancer Therapy – Cutaneous T-Cell Lymphoma (FACT-CTCL)
HSR25-182: Patient-Physician Communication About Adverse Events and Impact on Quality of Life to Foster Shared Decision-Making in Chronic Myeloid Leukemia
HSR25-183: Comparing Public Search Interest to Academic Research Interest in Diets and Cancer Using Google Trends and PubMed
HSR25-184: Association of Chimeric Antigen Receptor T-Cell Therapy and Social Vulnerability Index: A National View of Care Delivery Patterns
HSR25-186: A Systematic Review and Meta-Analysis of Randomized Controlled Trials to Evaluate the Risk of General Systemic Adverse Events in Locally Advanced Head and Neck Squamous Cell Carcinoma Treated With Immune Checkpoint Inhibitors
HSR25-187: Meta-Analysis of Phase III Randomized Controlled Trials to Evaluate the Risk of Gastrointestinal Adverse Events in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Treated With Amivantamab
HSR25-188: Comparative Risk of Acute Kidney Injury Among Cancer Patients Treated With Immunotherapy Using Large-Scale US Clinical Data
HSR25-189: Symptom Management and Patient Outcomes in Cardio-Oncology Population: A Scoping Review
HSR25-190: Clinical Experience With Immunotherapy in Advanced Solid Tumors – Real World Data From India
HSR25-191: A Correlation Research of Distress, Coping, and Quality of Life in Patients With Sarcoma
HSR25-192: Evaluation of Alternative Approaches to New Lesion Management and Measurable Disease Size Threshold on RANO-BM Response Assessment Following SRS for Brain Metastases
HSR25-193: Characterizing Influences to Multidisciplinary Team Care in Resectable Non-Small Cell Lung Cancer: A Qualitative Study
HSR25-194: Trends in Depression and Its Unequal Burden in Cancer Survivors With Socioeconomic Disparities.
HSR25-195: Risk of Venous and Arterial Thrombosis As Adverse Events in Patients Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: A Post-Market Analysis
HSR25-197: The Correlation of Resilience, Family Hardiness and Quality of Life of Patients With Soft Tissue Sarcoma and Family Caregivers Based on a Binary Perspective
HSR25-198: A Systematic Review and Meta-Analysis of Randomized Controlled Trials to Evaluate the Incidence of Hand-Foot Skin Reaction (HFSR) or Palmar-Plantar Erythrodysesthesia (PPE) in Patients With Cancers Treated With Fruquintinib
HSR25-199: Improving Under-Represented Rural Population Access to Oncology Care in the Community
HSR25-200: Evaluation of a Patient Navigation System on Cancer Treatment Milestones in a Rural Cancer Center
HSR25-201: The Impact of Cancer Treatment on Hearing Loss
HSR25-202: Epidemiology and Outcomes of Ventricular Arrhythmias in Patients With Hypercalcemia of Malignancy: A Population-Based Study
HSR25-203: Cost-Effectiveness Evaluation of Bruton Tyrosine Kinase Inhibitor (BTKi) Treatments Among Medicare Patients With Chronic Lymphocytic Leukemia (CLL) in First-Line (1L) and Relapsed/Refractory (R/R) Settings
HSR25-204: Clinical Characteristics and Prognosis Associated With Low PSA in Patients With De Novo Metastatic Hormone Sensitive Prostate Cancer
HSR25-207: Clinical Outcomes for Medicare Patients Following Hematopoietic Stem Cell Transplant: An Analysis of the National Inpatient Sample
HSR25-208: Clinical Outcomes for Medicaid Patients Following Hematopoietic Stem Cell Transplant: An Analysis of the National Inpatient Sample
Pre-Clinical Oncology
PCO25-209: Inhibition of Aurora A Kinase Restores Sensitivity to CDK 4/6 Inhibition of ER Positive Breast Cancers in Acquired Resistance PDX Model
PCO25-210: Design of Novel Antibody Drug Conjugates Using a Fully Humanized Monoclonal Antibody Targeting the Human Neuronal Pentraxin Receptor (YB800-ADCs) for Therapeutic Intervention in Oncology
PCO25-211: HIF-1α Inhibitor ACF Synergizes With PARP Inhibitors Through the Exacerbation of Transcription-Replication Conflicts in Ovarian Cancer
PCO25-212: Examining Molecular Features of Rare Brain Metastases Patient-Derived Xenograft Models
PCO25-213: Investigating Mechanisms of Antioxidant Treatment on Drug Resistant Breast Cancer
PCO25-215: The RKIP-HER2 Axis in Breast Cancer and Role in Immune Evasion
PCO25-216: The RKIP/HIF-1 Axis in Cancer Immune Evasion
Quality Improvement
QIM25-218: Improving Quality Outcomes Through a Hospitalist-Driven Malignant Hematology Service
QIM25-219: Identifying Barriers to Comprehensive Genomic Profiling for Patients in Academic and Community Oncology Centers
QIM25-220: The Use of Self Mixed Morphine Gel 0.125% for Topical Pain Control in Painful Cancer Lesions
QIM25-223: Acceptability, Facilitators, and Barriers to the Implementation of Screening and Brief Intervention for Alcohol Counseling in the Oncology Setting
QIM25-224: Demonstrating Value of a Shared Management Approach in the Care of Surgical Oncology Patients at an Academic Cancer Center
QIM25-225: Do Oncology Patients Want to Know Both Generic and Brand Drug Names?
QIM25-226: What Patients Anticipate About Working Out with Cancer: Qualitative Survey Results
QIM25-227: Evaluating Dosimetric Differences in Head and Neck Cancer Treatment: A RapidArc Approach With Flattening Filter-Free vs. Filtered Beams
QIM25-228: Utilizing Patient and Provider Perspectives in Psycho-Oncology Program Development and Quality Improvement
QIM25-230: Enhancing Communication Through Interprofessional Goal Concordant Care Training
QIM25-231: Implementation of an Emergent Response System in an Urban Oncology Infusion Unit: A Quality Improvement Initiative
QIM25-232: Extracellular Vesicles Evade the Antiangiogenic Effect of Bevacizumab in Ovarian Cancer
QIM25-233: Palliative Care in Action: Educating Through Storytelling
QIM25-234: Models and Outcomes of Multidisciplinary Clinics in Lung Cancer
QIM25-235: Exocrine Pancreatic Insufficiency (EPI) in Pancreatic Cancer Patients: Increasing Awareness and Screening
QIM25-236: Evaluation of Performance, Safety, and User Satisfaction of the Brevera® Breast Biopsy System: A Multicentre Study
QIM25-237: Supporting Oncologists in Capturing and Using Structured Oncology Data in Real-Time Using the Electronic Health Record (EHR)
QIM25-238: Navigating Barriers to ePRO Implementation in Community-Based Oncology Practices
QIM25-239: Hyperthermia Enhancing the Effect of Olaparib by Inducing Ferroptosis in Ovarian Cancer
QIM25-240: The New Threshold for Independence in Data Monitoring Committees (DMCs)
Trials in Progress
TIP25-241: Utilizing Augmented Reality as an Adjunct for Smoking Cessation: Trial in Progress
TIP25-242: The PREDICT II Registry: A Prospective Study to Evaluate the Clinical Utility of a 7-Gene Predictive Biosignature on Treatment Decisions in Patients With Ductal Carcinoma In Situ
TIP25-243: Randomized Study Evaluating Optimal Dose, Efficacy and Safety of E7386 + Lenvatinib Versus Treatment of Physicians' Choice in Advance/Recurrent Endometrial Carcinoma Previously Treated With Anti-PD-(L)1 Immunotherapy
TIP25-244: Comprehensive Outcomes for After Cancer Health (COACH) Study: 2024 Trial in Progress Updates
TIP25-246: Evaluating the Effect of a Mindfulness-Based Intervention on Metabolic and Immunological Biomarkers of Stress Among Caregivers of Allogeneic Hematopoietic Stem Cell Transplant Recipients: Trial in Progress
  • Collapse
  • Expand